Gemtuzumab-Ozogamicin-Related Impaired Hemoglobin-Haptoglobin Scavenging as On-Target/Off-Tumor Toxicity of Anti-CD33 AML Therapy: A Report of Two Cases

Gemtuzumab-ozogamicin (GO) is a humanized anti-CD33 antibody, which is conjugated to a cytotoxic calicheamicin. It is used to treat acute myeloid leukemia (AML) in combination with chemotherapy. We describe here two GO-treated acute myeloid leukemia (AML) cases: both patients suffered from a toxic s...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajala, Hanna L. M., Anttila, Veli-Jukka, Haapio, Mikko, Keränen, Mikko A. I., Wartiovaara-Kautto, Ulla, Räty, Riikka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007360/
https://www.ncbi.nlm.nih.gov/pubmed/33824768
http://dx.doi.org/10.1155/2021/6641349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007360/
https://www.ncbi.nlm.nih.gov/pubmed/33824768
http://dx.doi.org/10.1155/2021/6641349

Ejemplares similares